Skip to main content

Table 3 Minimum inhibitory concentrations (MIC90, MIC range [mg/L]) and antimicrobial susceptibility (%S) and resistance (%R) of Gram-negative isolates

From: The Tigecycline Evaluation and Surveillance Trial; assessment of the activity of tigecycline and other selected antibiotics against Gram-positive and Gram-negative pathogens from France collected between 2004 and 2016

Organism/ Antimicrobial 2004–2016 2013–2016
MIC90 (mg/L) MIC Range (mg/L) % S % R MIC90 (mg/L) MIC Range (mg/L) % S % R
Enterobacter spp. N = 3424 N = 924
Amikacin 4 ≤0.5 to ≥128 96.9 1.1 4 ≤0.5 to ≥128 98.4 0.8
Cefepimea 16 ≤0.5 to ≥64 69.5 15.8 32 ≤0.5 to ≥64 67.1 19.8
Ceftriaxone 64 ≤0.06 to ≥128 50.9 45.6 64 ≤0.06 to 64 49.1 47.3
Levofloxacinc ≤16 ≤0.008 to ≥16 71.5 25.0 8 ≤0.008 to ≥16 75.8 19.7
Meropenem (N = 3113)b 0.25 ≤0.06 to ≥32 99.2 0.3 0.25 ≤0.06 to ≥32 99.4 0.2
Minocycline 16 ≤0.5 to ≥32 8 ≤0.5 to ≥32
Pip-tazc 128 ≤0.06 to ≥256 60.7 30.5 128 ≤0.06 to ≥256 64.7 25.6
Tigecycline 2 0.06 to 16 86.3 5.2 2 0.06 to 16 89.5 3.5
E. coli N = 3527 N = 965
Amikacin 4 ≤0.5 to ≥128 98.1 0.5 4 ≤0.5 to ≥128 98.4 0.2
Amox-clav 32 0.25 to ≥64 72.1 27.9 16 0.5 to ≥64 75.1 24.9
Ampicillin ≥64 ≤0.5 to ≥64 37.9 62.1 ≥64 ≤0.5 to ≥64 38.5 61.5
Cefepimea 8 ≤0.5 to ≥64 82.5 12.4 16 ≤0.5 to ≥64 80.7 13.8
Ceftriaxonea 64 ≤0.06 to ≥128 82.6 16.8 64 ≤0.06 to 64 81.3 18.4
Levofloxacin ≥16 ≤0.008 to ≥16 78.5 20.2 8 ≤0.008 to ≥16 79.6 19.4
Meropenem (N = 3203)b ≤0.06 ≤0.06 to 8 99.9 0.0 ≤0.06 ≤0.06 to 8 99.9 0.0
Minocycline 8 ≤0.5 to ≥32 8 ≤0.5 to ≥32
Pip-taz 16 ≤0.06 to ≥256 89.6 7.2 8 ≤0.06 to ≥256 91.6 6.2
Tigecycline 0.5 ≤0.008 to 16 99.4 0.1 0.25 0.03 to 16 99.5 0.1
E. coli, ESBL N = 489 N = 156
Amikacin 8 ≤0.5 to ≥128 92.6 2.2 8 1 to ≥128 95.5 0.6
Amox-clavc 32 2 to ≥64 45.8 54.2 16 2 to ≥64 59.0 41.0
Ampicillin ≥64 32 to ≥64 0.0 100 ≥64 64 to ≥64 0.0 100
Cefepime ≥64 ≤0.5 to ≥64 3.9 78.3 ≥64 1 to ≥64 3.2 79.5
Ceftriaxone ≥128 2 to ≥128 0.0 99.2 64 4 to 64 0.0 100
Levofloxacin ≥16 ≤0.008 to ≥16 37.8 59.7 ≥16 0.015 to ≥16 42.3 55.1
Meropenem (N = 472)b ≤0.06 ≤0.06 to 2 100 0.0 ≤0.06 ≤0.06 to 1 100 0.0
Minocycline 16 ≤0.5 to ≥32 16 ≤0.5 to ≥32
Pip-tazc 32 0.25 to ≥256 78.3 12.7 16 0.25 to ≥256 88.5 3.8
Tigecycline 0.5 0.03 to 2 99.2 0.0 0.25 0.03 to 2 99.4 0.0
H. influenzae N = 1786 N = 494
Amikacin 8 ≤0.5 to 64 8 ≤0.5 to 16
Amox-clav 1 ≤0.12 to 16 99.2 0.8 1 ≤0.12 to 4 99.0 1.0
Ampicillin 32 ≤0.5 to ≥64 75.4 24.6 32 ≤0.5 to ≥64 74.1 25.9
Cefepime ≤0.5 ≤0.5 to 2 ≤0.5 ≤0.5 to 2
Ceftriaxone ≤0.06 ≤0.06 to 4 98.6 1.4 ≤0.06 ≤0.06 to 2 99.4 0.4
Levofloxacin 0.015 ≤0.008 to 8 98.4 1.6 0.015 ≤0.008 to 8 98.6 1.4
Meropenem (N = 1629)b 0.12 ≤0.06 to 0.5 100 0.0 0.12 ≤0.06 to 0.5 100 0.0
Minocycline 1 ≤0.5 to 16 91.8 1.6 1 ≤0.5 to 4 93.1 0.8
Pip-taz ≤0.06 ≤0.06 to 0.5 ≤0.06 ≤0.06 to 0.5
Tigecycline 0.25 ≤0.008 to 4 0.25 ≤0.008 to 0.25
H. influenzae, BL Positive N = 410 N = 122
Amikacin 8 ≤0.5 to 32 8 ≤0.5 to 16
Amox-clav 2 ≤0.12 to 16 97.3 2.7 2 ≤0.12 to 4 95.9 4.1
Ampicillin ≥64 ≤0.5 to ≥64 0.5 99.5 ≥64 ≤0.5 to ≥64 0.8 99.2
Cefepime ≤0.5 ≤0.5 to 2 ≤0.5 ≤0.5 to 2
Ceftriaxone ≤0.06 ≤0.06 to 4 97.8 2.2 ≤0.06 ≤0.06 to 2 99.2 0.8
Levofloxacin 0.03 ≤0.008 to 1 97.8 2.2 0.015 ≤0.008 to 0.5 97.5 2.5
Meropenem (N = 378)b 0.12 ≤0.06 to 0.5 100 0.0 0.12 ≤0.06 to 0.5 100 0.0
Minocycline 1 ≤0.5 to 16 93.2 0.5 1 ≤0.5 to 2 93.4 0.0
Pip-taz ≤0.06 ≤0.06 to 0.5 ≤0.06 ≤0.06 to 0.5
Tigecycline 0.25 ≤0.008 to 0.5 0.25 ≤0.008 to 0.25
K. oxytoca N = 975 N = 225
Amikacin 4 ≤0.5 to ≥128 98.9 0.4 4 ≤0.5 to 16 99.1 0.0
Amox-clav 32 0.25 to ≥64 79.8 20.2 16 0.25 to ≥64 82.2 17.8
Cefepime 2 ≤0.5 to ≥64 88.4 3.9 2 ≤0.5 to ≥64 88.4 4.9
Ceftriaxone 8 ≤0.06 to ≥128 83.2 14.5 4 ≤0.06 to 64 85.8 12.0
Levofloxacin 1 ≤0.008 to ≥16 89.5 8.4 0.25 0.015 to ≥16 94.2 4.4
Meropenem (N = 872)b ≤0.06 ≤0.06 to ≥32 99.8 0.1 ≤0.06 ≤0.06 to 1 100 0.0
Minocycline 4 ≤0.5 to ≥32 2 ≤0.5 to 16
Pip-taz ≥256 ≤0.06 to ≥256 84.0 15.1 64 0.25 to ≥256 87.6 11.6
Tigecycline 1 0.015 to 8 95.8 1.0 0.5 0.12 to 4 96.9 0.9
K. pneumoniae N = 2398 N = 690
Amikacin 4 ≤0.5 to ≥128 96.5 1.5 4 ≤0.5 to ≥128 96.8 1.7
Amox-clava 32 0.5 to ≥64 68.6 31.4 32 1 to ≥64 61.4 38.6
Cefepimea ≥64 ≤0.5 to ≥64 72.1 23.4 ≥64 ≤0.5 to ≥64 59.9 35.5
Ceftriaxonea 64 ≤0.06 to ≥128 70.3 28.7 64 ≤0.06 to 64 58.4 41.4
Levofloxacina 8 ≤0.008 to ≥16 76.1 20.0 8 0.015 to ≥16 72.3 23.2
Meropenema (N = 2186)b 0.12 ≤0.06 to ≥32 99.4 0.4 0.12 ≤0.06 to ≥32 98.8 1.0
Minocycline 16 ≤0.5 to ≥32 16 ≤0.5 to ≥32
Pip-taz 64 0.12 to ≥256 81.9 13.1 32 0.12 to≥256 84.1 10.3
Tigecyclinea 2 0.06 to 16 87.4 5.0 2 0.06 to 8 86.2 7.0
K. pneumoniae, ESBL N = 622 N = 265
Amikacin 8 ≤0.5 to ≥128 90.0 4.2 8 ≤0.5 to ≥128 94.7 3.8
Amox-clav 32 1 to ≥64 19.0 81.0 32 1 to ≥64 20.8 79.2
Cefepimea ≥64 ≤0.5 to ≥64 5.0 85.0 ≥64 ≤0.5 to ≥64 3.8 86.8
Ceftriaxone ≥128 ≤0.06 to ≥128 1.3 98.4 64 ≤0.06 to 64 1.1 98.9
Levofloxacinc ≥16 0.03 to ≥16 30.2 61.1 ≥16 0.03 to ≥16 38.9 50.9
Meropenem (N = 603)b 0.12 ≤0.06 to ≥32 99.0 0.3 0.12 ≤0.06 to 16 99.2 0.4
Minocycline ≥32 ≤0.5 to ≥32 ≥32 ≤0.5 to ≥32
Pip-tazc ≥256 0.25 to ≥256 54.0 32.8 128 0.25 to ≥256 68.7 18.5
Tigecycline 2 0.12 to 8 79.4 7.2 2 0.12 to 8 80.0 7.9
S. marcescens N = 1345 N = 360
Amikacin 4 ≤0.5 to ≥128 97.3 1.1 4 ≤0.5 to 64 98.3 0.6
Cefepime ≤0.5 ≤0.5 to ≥64 94.5 2.2 ≤0.5 ≤0.5 to ≥32 94.7 1.9
Ceftriaxone 8 ≤0.06 to ≥128 82.2 13.8 2 ≤0.06 to 64 86.9 8.9
Levofloxacinc 2 ≤0.008 to ≥16 84.2 10.6 1 ≤0.008 to ≥16 89.4 5.6
Meropenem (N = 1227)b 0.12 ≤0.06 to ≥32 99.1 0.1 0.12 ≤0.06 to 2 100 0.0
Minocycline 8 ≤0.5 to ≥32 4 ≤0.5 to ≥32
Pip-taz 16 ≤0.06 to ≥256 89.9 6.2 8 ≤0.06 to 128 93.9 3.3
Tigecycline 2 0.015 to 8 80.7 2.6 2 0.03 to 4 80.3 1.1
A. baumannii N = 1496 N = 270
Amikacin ≥128 ≤0.5 to ≥128 74.9 19.9 ≥128 1 to ≥128 73.7 20.4
Cefepime 32 ≤0.5 to ≥64 ≥64 ≤0.5 to ≥64
Ceftazidime (N = 1488) ≥64 ≤1 to ≥64 32 ≤1 to 32
Ceftriaxone ≥128 ≤0.06 to ≥128 64 2 to 64
Levofloxacin ≥16 ≤0.008 to ≥16 54.5 43.2 ≥16 ≤0.008 to ≥16 56.7 42.6
Meropenema (N = 1326)b ≥32 ≤0.06 to ≥32 81.0 11.8 ≥32 0.12 to ≥32 74.1 20
Minocycline 8 ≤0.5 to ≥32 8 ≤0.5 to ≥32
Pip-taz ≥256 ≤0.06 to ≥256 ≥256 ≤0.06 to ≥256
Tigecycline 1 ≤0.008 to 8 1 0.03 to 2
A. baumannii MDR N = 93 N = 35
Amikacin ≥128 32 to ≥128 0.0 100 ≥128 32 to ≥128 0.0 100
Cefepime ≥64 8 to ≥64 ≥64 8 to ≥64
Ceftazidime (N = 92) ≥64 ≤1 to ≥64 32 2 to 32
Ceftriaxone ≥128 64 to ≥128 64 64 to 64
Levofloxacin ≥16 2 to ≥16 0.0 100 ≥16 2 to ≥16 0.0 100
Meropenem (N = 92)b ≥32 16 to ≥32 0.0 100 ≥32 16 to ≥32 0.0 100
Minocycline 16 ≤0.5 to ≥32 16 ≤0.5 to ≥32
Pip-taz ≥256 ≤0.06 to ≥256 ≥256 64 to ≥256
Tigecycline 4 0.12 to 4 2 0.25 to 2
P. aeruginosa N = 2734 N = 738
Amikacin 16 ≤0.5 to ≥128 88.5 6.9 8 ≤0.5 to ≥128 91.1 5.1
Cefepime 32 ≤0.5 to ≥64 77.8 22.2 16 ≤0.5 to ≥64 79.8 20.2
Ceftazidime (N = 2730) 32 ≤1 to ≥64 77.2 22.8 32 ≤1 to 32 80.2 19.8
Levofloxacinc ≥16 ≤0.008 to ≥16 60.6 39.4 ≥16 0.015 to ≥16 65.7 34.3
Meropenem (N = 2474) 8 ≤0.06 to ≥32 74.6 8.7 16 ≤0.06 to ≥32 75.2 10.0
Pip-tazc 128 ≤0.06 to ≥256 74.4 25.6 128 ≤0.06 to ≥256 78.7 21.3
Tigecycline 16 ≤0.008 to ≥32 16 0.12 to 16
P. aeruginosa MDR N = 271 N = 68
Amikacin ≥128 1 to ≥128 31.4 58.3 ≥128 2 to ≥128 38.2 50.0
Cefepime ≥64 2 to ≥64 14.0 86.0 ≥64 4 to ≥64 8.8 91.2
Ceftazidime ≥64 2 to ≥64 21.4 78.6 32 4 to 32 23.5 76.5
Levofloxacin ≥16 0.5 to ≥16 1.5 98.5 ≥16 2 to ≥16 0.0 100
Meropenema (N = 258)b ≥32 ≤0.06 to ≥32 17.8 66.7 ≥32 0.25 to ≥32 11.8 82.4
Pip-tazc ≥256 0.5 to ≥256 14.0 86.0 ≥256 1 to ≥256 20.6 79.4
Tigecycline ≥32 1 to ≥32 16 2 to 16
  1. – indicates no susceptibility breakpoints are available for this agent
  2. a indicates statistically significant decrease in susceptibility (p < 0.01) from 2004 to 2016
  3. b Meropenem was introduced to the testing panel in 2006, replacing imipenem; N values of activity against organisms collected from 2006 to 2016 are given
  4. c indicates statistically significant increase in susceptibility (p < 0.01) from 2004 to 2016
  5. Amox-clav, amoxicillin-clavulanic acid, BL, β-lactamase, ESBL, extended-spectrum β-lactamase, MDR, multidrug-resistant, MIC, minimum inhibitory concentration, MIC90, minimum inhibitory concentration required to inhibit growth of 90% of isolates (mg/L), Pip-taz, piperacillin-tazobactam, R, resistant, S, susceptible